« Return to News | Ethics/Regulatory

PhRMA issues statement on biosimilar user fees

Thursday, December 8, 2011 10:20 AM

Pharmaceutical Research and Manufacturers of America (PhRMA) vice president Sascha Haverfield-Gross has issued the following statement about user fees for biosimilars:

“PhRMA is pleased that the Food and Drug Administration (FDA) has announced plans to solicit stakeholder input at an upcoming public meeting about the proposed user fees and performance goals for biosimilars. We endorse a clear, science-based, separately funded regulatory program for biosimilars that is supported by a mix of appropriations dollars and user fees."

“PhRMA has long backed the establishment of an approval pathway for biosimilars that is conducive to the thorough assessment of the safety and efficacy of these medicines. We look forward to participating in the FDA’s public meeting and continued work with the agency as it implements a regulatory pathway that ensures the safety, purity, and potency of biosimilar products."

“The performance goals letter published today demonstrates FDA’s commitment to a science-driven approach for biosimilars. The letter provides for FDA and sponsor meetings for the substantive review of biosimilar development plans. It also includes a special protocol assessment mechanism for clinical trials intended to establish biosimilarity and/or interchangeability with the innovator biologic product. This provision will help to ensure that clinical trials are designed to thoroughly assess the safety and efficacy of biosimilar medicines, in accordance with the FDA’s high regulatory and scientific standards.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.